Vivo Capital’s Zymeworks ZYME Stock Holding History

Vivo Capital’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-286,064	Closed	-$1.52M	–	53
2022 Q2	$1.52M	Hold	286,064	–	–	0.15%	45
2022 Q1	$1.87M	Hold	286,064	–	–	0.13%	50
2021 Q4	$4.69M	Hold	286,064	–	–	0.28%	47
2021 Q3	$8.31M	Hold	286,064	–	–	0.37%	44
2021 Q2	$9.92M	Hold	286,064	–	–	0.43%	41
2021 Q1	$9.03M	Hold	286,064	–	–	0.32%	44
2020 Q4	$13.5M	Sell	286,064 -354,347	-55%	-$16.5M	0.6%	37
2020 Q3	$29.8M	Sell	640,411 -93,750	-13%	-$3.22M	1.72%	14
2020 Q2	$26.5M	Sell	734,161 -367,075	-33%	-$13.5M	1.9%	14
2020 Q1	$39.1M	Buy	+1,101,236	New	+$45.1M	3.54%	6
2019 Q3	–	Sell	-1,453,467	Closed	-$32M	–	30
2019 Q2	$32M	Buy	1,453,467 +833,333	+134%	+$15.3M	3%	9
2019 Q1	$10M	Hold	620,134	–	–	1%	25
2018 Q4	$9.1M	Hold	620,134	–	–	1.16%	24
2018 Q3	$9.74M	Hold	620,134	–	–	0.98%	26
2018 Q2	$9.17M	Buy	+620,134	New	+$9.61M	1.18%	24

Other funds holding ZYME

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Vivo Capital's ZYME Position: Q3 2022 in Review

Vivo Capital sold out of Zymeworks (ZYME) in Q3 2022, closing a stake of 286,064 shares — an estimated $1.52M sold.

Vivo Capital first reported a position in ZYME in Q2 2018 and held it in 15 quarters. The position peaked at $39.1M in Q1 2020. 91 funds tracked by Wall St. Rank hold ZYME as of Q3 2022.

Vivo Capital reported no remaining Zymeworks position as of Q3 2022 after selling out during the quarter.
Vivo Capital sold 286,064 Zymeworks shares in Q3 2022, an estimated $1.52M.
Vivo Capital first reported a position in Zymeworks in Q2 2018 and held it in 15 quarters.
Vivo Capital's Zymeworks position peaked at $39.1M in Q1 2020.
91 funds tracked by Wall St. Rank held Zymeworks as of Q3 2022.

Based on Vivo Capital's 13F filing for Q3 2022, filed 14 Nov 2022.